Kestra Medical Technologies
KMTS
26.49
-0.61
-2.25%
Kestra Medical Technologies
US · KMTS
#2924 by market cap
Listed 2025
26.49
-0.61
-2.25%
Live - 5344 symbols - heartbeat 466s ago
· 2026-10-07 19:54
After-hours
26.49
0.00%
- Market cap
- 1.58B
- P/E (TTM)i
- -10.47
- P/Bi
- 7.10
- EPSi
- -2.43
- Div yieldi
- 0.00%
- 52W posi
- 72%
Reader sentiment
Are you bullish or bearish on KMTS?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 6.64, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 6 years
Latest year +59.03% YoY
Margins
- Gross margin
- 51.37%
- Operating margin
- -141.64%
- Net margin
- -138.36%
Key ratios & quality
- Enterprise valuei
- 1.42B
- Altman Z-Scorei
- 6.64
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2020 | 2021 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | 7.63M | 27.81M | 59.82M | 95.13M |
| Gross profit | -- | -- | -10.65M | 362.00K | 24.21M | 48.86M |
| Selling & admin expenses | 6.52M | 13.90M | 54.01M | 69.94M | 114.94M | 164.12M |
| Research & development | 22.80M | 18.81M | 15.76M | 15.49M | 15.65M | 19.48M |
| Operating profit | -29.32M | -32.71M | -80.42M | -85.06M | -106.38M | -134.74M |
| Pretax profit | -29.32M | -33.91M | -84.22M | -94.10M | -113.68M | -131.32M |
| Tax | 148.00K | 187.00K | 15.00K | 24.00K | 135.00K | 294.00K |
| Net profit | -29.47M | -34.10M | -84.24M | -94.12M | -113.81M | -131.61M |
| Basic EPS | -1 | -2 | -4 | -5 | -5 | -2 |
| Diluted EPS | -1.48 | -1.71 | -4.36 | -5.07 | -5.13 | -2.43 |
| Line item | 2025-04 | 2025-07 | 2025-10 | 2026-01 | 2026-04 | 2026-07 |
|---|---|---|---|---|---|---|
| Revenue | 17.23M | 19.37M | 22.57M | 24.55M | 28.64M | 30.97M |
| Gross profit | 7.63M | 8.85M | 11.42M | 12.91M | 15.68M | 17.50M |
| Selling & admin expenses | 50.46M | 33.73M | 38.30M | 42.70M | 49.39M | 48.36M |
| Research & development | 5.39M | 4.00M | 4.88M | 4.97M | 5.63M | 6.80M |
| Operating profit | -48.21M | -28.88M | -31.76M | -34.77M | -39.34M | -37.66M |
| Pretax profit | -51.01M | -25.79M | -32.75M | -34.13M | -38.64M | -44.04M |
| Tax | 102.00K | 33.00K | 34.00K | 35.00K | 192.00K | 50.00K |
| Net profit | -51.11M | -25.83M | -32.79M | -34.17M | -38.84M | -44.09M |
| Basic EPS | -2 | -1 | -1 | -1 | -1 | -1 |
| Diluted EPS | -2.21 | -0.50 | -0.64 | -0.61 | -0.67 | -0.75 |
Balance sheet
| Line item | 2020 | 2021 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Total current assets | 6.17M | 26.20M | 18.42M | 14.91M | 255.33M | 222.36M |
| Cash & ST investments | 5.76M | 24.34M | 14.81M | 8.25M | 237.60M | 196.43M |
| Inventory | -- | -- | 2.11M | 3.29M | 6.57M | 6.71M |
| Total assets | 7.87M | 30.52M | 38.66M | 45.95M | 295.74M | 358.47M |
| Total current liabilities | 4.02M | 6.61M | 36.74M | 32.97M | 37.98M | 50.37M |
| Short-term debt | 452.00K | 1.06M | 21.81M | -- | 187.00K | 31.00K |
| Long-term debt | -- | 20.24M | 17.32M | 42.54M | 41.10M | 42.65M |
| Total liabilities | 4,016,000.00 | 28,756,000.00 | 156,234,000.00 | 255,326,000.00 | 90,338,000.00 | 98,807,000.00 |
| Total equity | 3.86M | 1.77M | -117.58M | -209.38M | 205.41M | 259.66M |
| Retained earnings | -135.98M | -170.08M | -312.32M | -406.44M | -520.25M | -651.86M |
| Line item | 2025-04 | 2025-07 | 2025-10 | 2026-01 | 2026-04 | 2026-07 |
|---|---|---|---|---|---|---|
| Total current assets | 255.33M | 220.69M | 195.41M | 314.06M | 222.36M | 226.27M |
| Cash & ST investments | 237.60M | 201.21M | 175.42M | 291.32M | 196.43M | 198.91M |
| Inventory | 6.57M | 6.80M | 6.92M | 6.83M | 6.71M | 7.44M |
| Total assets | 295.74M | 266.30M | 246.70M | 379.34M | 358.47M | 347.36M |
| Total current liabilities | 37.98M | 32.26M | 35.76M | 42.93M | 50.37M | 48.27M |
| Short-term debt | 187.00K | 36.00K | 53.00K | 10.00K | 31.00K | 23.00K |
| Long-term debt | 41.10M | 41.49M | 41.87M | 42.26M | 42.65M | 72.50M |
| Total liabilities | 90,338,000.00 | 82,137,000.00 | 82,620,000.00 | 91,353,000.00 | 98,807,000.00 | 124,998,000.00 |
| Total equity | 205.41M | 184.16M | 164.08M | 287.99M | 259.66M | 222.36M |
| Retained earnings | -520.25M | -546.08M | -578.86M | -613.03M | -651.86M | -695.95M |
Cash flow
| Line item | 2020 | 2021 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Operating cash flow | -30.29M | -29.90M | -69.64M | -72.24M | -77.61M | -81.70M |
| Depreciation & amortization | 478.00K | 420.00K | 4.86M | 11.56M | 7.97M | 8.71M |
| Free cash flow | -30.53M | -30.23M | -85.10M | -84.75M | -101.20M | -117.12M |
| Dividends paid | -183.00K | -187.00K | -671.00K | -799.00K | -1.65M | -323.00K |
| Stock buybacks / issuance | -- | -- | -- | 0 | 215.79M | 149.29M |
| Ending cash balance | 6.27M | 24.85M | 15.32M | 8.58M | 237.93M | 100.04M |
| Line item | 2025-04 | 2025-07 | 2025-10 | 2026-01 | 2026-04 | 2026-07 |
|---|---|---|---|---|---|---|
| Operating cash flow | -24.06M | -26.27M | -18.34M | -18.37M | -18.72M | -32.30M |
| Depreciation & amortization | 1.84M | 2.03M | 2.37M | 1.98M | 2.33M | 2.66M |
| Free cash flow | -31.47M | -34.54M | -25.84M | -28.35M | -28.39M | -40.63M |
| Dividends paid | -6.00K | 0 | 0 | -25.00K | -298.00K | -172.00K |
| Stock buybacks / issuance | 215.79M | -- | -- | -- | 0 | -- |
| Ending cash balance | 237.93M | 201.55M | 175.76M | 291.66M | 100.04M | 68.89M |
Returns & efficiency
| Line item | 2020 | 2021 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| ROE %i | -763.99 | -1,212.91 | -- | -- | -- | -56.60 |
| ROA %i | -374.28 | -177.63 | -224.38 | -238.38 | -73.83 | -40.24 |
| ROIC %i | -683.85 | -229.90 | -- | -- | -- | -47.50 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -1,030.07 | -315.91 | -177.12 | -130.11 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 1.54 | 3.96 | 0.50 | 0.45 | 6.72 | 4.41 |
| Quick ratioi | 1.43 | 3.68 | 0.40 | 0.31 | 6.47 | 4.19 |
| Debt / assetsi | 5.74 | 74.86 | 101.24 | 98.30 | 14.98 | 13.05 |
| LT debt / equityi | -- | 1,233.75 | -- | -- | 21.48 | 18.01 |
| Interest coveragei | -- | -28.04 | -13.96 | -14.10 | -13.70 | -16.40 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | 131.88 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Line item | 2025-04 | 2025-07 | 2025-10 | 2026-01 | 2026-04 | 2026-07 |
|---|---|---|---|---|---|---|
| ROE %i | -- | -70.43 | -- | -2,125.73 | -56.60 | -73.74 |
| ROA %i | -73.83 | -48.70 | -75.40 | -60.79 | -40.24 | -48.85 |
| ROIC %i | -- | -55.90 | -- | -276.95 | -47.50 | -56.99 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -177.12 | -167.74 | -166.90 | -162.71 | -130.11 | -133.05 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 6.72 | 6.84 | 5.47 | 7.32 | 4.41 | 4.69 |
| Quick ratioi | 6.47 | 6.52 | 5.20 | 7.08 | 4.19 | 4.44 |
| Debt / assetsi | 14.98 | 16.74 | 18.16 | 12.27 | 13.05 | 22.01 |
| LT debt / equityi | 21.48 | 24.19 | 27.27 | 16.16 | 18.01 | 34.37 |
| Interest coveragei | -13.70 | -14.33 | -16.85 | -18.26 | -16.40 | -18.78 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Single segment100.00%
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.